European Monitoring Centre for Drugs and Drug Addiction. (2016) Report on the risk assessment of 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (α-pyrrolidinovalerophenone, α-PVP). Luxembourg: Publications Office of the European Union. Risk Assessments 18.
| Preview | Title | Contact |
|---|---|---|
|
PDF (Risk assessment a-pvp)
638kB |
This publication presents the data and findings of the risk assessment on α-PVP (1-phenyl- 2-(1-pyrrolidinyl)-1-pentanone), carried out by the extended Scientific Committee of the EMCDDA on 18 November 2015. α-PVP is the eleventh new psychoactive substance to be risk assessed under the terms of Council Decision 2005/387/JHA. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 27 June 2016, the Council decided that α-PVP should be subject to control measures across the Member States.
Table of contents
- Foreword
- EMCDDA actions on monitoring and responding to new drugs
- EMCDDA–Europol Joint Report on α-PVP: a summary
- Risk Assessment Report of a new psychoactive substance: α-PVP
- Annex 1: Technical report on α-PVP
- Council Decision on subjecting α-PVP to control measures
- Participants of the risk assessment meeting
Repository Staff Only: item control page